Item 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES


(a)	The following documents are filed as part of this Annual Report:

Financial Statements.

The consolidated financial statements listed in Part II, Item 8 of this Annual Report.

Financial Statement Schedules.

For the three fiscal years ended December 31, 2019, Schedule II – Valuation and Qualifying Accounts.

Financial statement schedules not listed above have been omitted because information required to be set forth therein is not applicable, not required, or the information required by such schedules is shown in the consolidated financial statements or the notes thereto.

Exhibits.



Exhibit Number		Exhibit Description		Incorporated by Reference					Provided Herewith
Form	File No.		Date of First Filing		Exhibit Number
3.01		Registrant’s Restated Certificate of Incorporation.		S-1/A		333-122454	March 3, 2005	3.03
3.02		Amendment No. 1 to Registrant’s Restated Certificate of Incorporation.		DEF 14 A		000-51222	April 20, 2017	Appendix B
3.03		Registrant’s Amended and Restated Bylaws.		8-K		000-51222	November 25, 2014	3.01
4.01		Form of Specimen Certificate for Registrant’s common stock.		S-1/A		333-122454	March 24, 2005	4.01
4.02		Indenture, dated as of May 12, 2017, between DexCom, Inc. and U.S. Bank National Association (including the form of 0.75% Convertible Senior Notes due 2022)		8-K		000-51222	May 12, 2017	4.1
4.03		Indenture, dated as of November 30, 2019, between DexCom, Inc. and U.S. Bank National Association (including the form of 0.75% Convertible Senior Notes due 2023)		8-K		000-51222	December 3, 2018	4.1
4.04		Description of Securities Registered Under Section 12 of the Exchange Act.							X
10.01		Form of Indemnity Agreement between Registrant and each of its directors and executive officers.		S-1		333-122454	February 1, 2005	10.01
10.02		Office Lease Agreement, dated March 31, 2006, between DexCom, Inc. and Kilroy Realty, L.P.		8-K		000-51222	April 7, 2006	99.01
10.03		Offer letter between DexCom, Inc. and Steven R. Pacelli dated April 10, 2006.*		8-K		000-51222	April 13, 2006	99.01
10.04		Form of Amended and Restated Executive Change of Control & Severance Agreement.*		10-K		000-51222	March 5, 2009	10.20
10.05		Non-Exclusive Distribution Agreement, between RGH Enterprises, Inc. and DexCom, Inc., dated April 30, 2008.**		10-Q		000-51222	August 3, 2009	10.23
10.06		Amended and Restated Development, Manufacturing, Licensing and Supply Agreement, between DSM PTG, Inc. and DexCom, Inc., dated February 19, 2010.**		10-K		000-51222	March 9, 2010	10.25
10.07		First Amendment to Office Lease between DexCom, Inc. and Kilroy Realty, L.P., dated August 18, 2010.		10-Q		000-51222	November 4, 2010	10.27



Exhibit Number		Exhibit Description		Incorporated by Reference					Provided Herewith
Form	File No.		Date of First Filing		Exhibit Number
10.08		Amendment Number One to Non-Exclusive Distribution Agreement, between RGH Enterprises, Inc. and DexCom, Inc., dated March 29, 2011.**		10-Q/A		000-51222	July 1, 2011	10.26
10.09		Offer letter between DexCom, Inc. and Kevin Sayer dated May 3, 2011.*		10-Q		000-51222	August 3, 2011	10.28
10.10		Amendment Number Two to Non-Exclusive Distribution Agreement between RGH Enterprises, Inc. and DexCom, Inc., dated March 28, 2013.**		10-Q		000-51222	May 1, 2013	10.27
10.11		Amendment Number Three to Non-Exclusive Distribution Agreement between RGH Enterprises, Inc. and DexCom, Inc., dated December 4, 2013.**		10-K		000-51222	February 20, 2014	10.28
10.12		Non-Exclusive Distribution Agreement between Dexcom, Inc. and Diabetes Specialty Center, LLC dated October 12, 2009, as amended on September 30, 2010, October 11, 2011, November 14, 2012 and November 1, 2013.**		10-K		000-51222	February 20, 2014	10.29
10.13		Settlement and License Agreement by and among Abbott Diabetes Care, Inc. and DexCom, Inc., dated July 2, 2014.		10-Q		000-51222	August 6, 2014	10.31
10.14		Amendment No. 5 to Non-Exclusive Distribution Agreement between DexCom, Inc. and Diabetes Specialty Center, LLC, dated March 14, 2014.		10-Q		000-51222	August 6, 2014	10.32
10.15		Second Amendment to Office Lease between DexCom, Inc. and Kilroy Realty, L.P., dated October 1, 2014.		10-K		000-51222	February 25, 2015	10.32
10.16		2015 Employee Stock Purchase Plan		DEF 14A		000-51222	April 13, 2015	Appendix A
10.17		Form of Subscription Agreement under 2015 Employee Stock Purchase Plan		8-K		000-51222	June 2, 2015	10.2
10.18		Sublease between DexCom, Inc. and Entropic Communications, LLC dated February 1, 2016.		10-Q		000-51222	April 27, 2016	10.36
10.19		Amended and Restated Non-Exclusive Distribution Agreement with Byram Healthcare dated February 1, 2016.**		10-Q		000-51222	April 27, 2016	10.37
10.20		Industrial Net Lease, Broadway dated April 28, 2016, by and between PRA/LB, L.L.C. and DexCom, Inc.		10-Q		000-51222	August 2, 2016	10.39
10.21		Standard Form of Agreement dated May 2, 2016, by and between DexCom, Inc. and Skanska USA Building Inc.		10-Q		000-51222	August 2, 2016	10.40
10.22		Amendment to Non-Exclusive Distribution Agreement dated April 30, 2016 by and between RGH Enterprises, Inc. d/b/a Cardinal Health at Home and DexCom, Inc. **		10-Q		000-51222	August 2, 2016	10.41
10.23		Amendment No. 1 to Collaboration and License Agreement dated October 25, 2016 by and between DexCom, Inc. and Verily Life Sciences LLC (formerly Google Life Sciences LLC).		10-K		000-51222	February 28, 2017	10.42
10.24		Severance and Change in Control Plan.		8-K		000-51222	June 6, 2017	10.20



Exhibit Number		Exhibit Description		Incorporated by Reference					Provided Herewith
Form	File No.		Date of First Filing		Exhibit Number
10.25		Form of Participation Agreement to the Severance and Change in Control Plan.		8-K		000-51222	June 6, 2017	10.30
10.26		First Amendment to Credit Agreement dated June 17, 2016 by and among DexCom, Inc., the Lenders, and JPMorgan Chase Bank, as Administrative Agent.		10-Q		000-51222	August 1, 2017	10.46
10.27		Standard Form of Agreement dated May 1, 2017, by and between DexCom, Inc. and Skanska USA Building Inc.		10-Q		000-51222	August 1, 2017	10.47
10.28		Offer Letter for Quentin S. Blackford dated July 28, 2017. *		8-K		000-51222	August 1, 2017	10.10
10.29		Form of Indemnity Agreement		10-Q		000-51222	August 1, 2017	10.43
10.30		Form of RSU Grant Agreement 2015 Plan Global Double Trigger		10-K		000-51222	February 27, 2018	10.51
10.31		Form of RSU Grant Agreement 2015 Plan Global General		10-K		000-51222	February 27, 2018	10.52
10.32		Amended and Restated Collaboration and License Agreement dated November 20, 2018 by and between DexCom, Inc., Verily Life Sciences LLC (an Alphabet Company) and Verily Ireland Limited.**		10-K		000-51222	February 21, 2019	10.60
10.33		Amended and Restated Credit Agreement dated December 19, 2018 by and among DexCom, Inc., Bank of America, Silicon Valley Bank and Union Bank, and JPMorgan Chase Bank, as Administrative Agent.		10-K		000-51222	February 21, 2019	10.61
10.34		Amended and Restated 2015 Equity Incentive Plan		8-K		000-51222	June 4, 2019	10.01
10.35		Executive Deferred Compensation Plan		8-K		000-51222	June 4, 2019	10.02
10.36		Form of RSU Grant Agreement 2015 Plan (Board Members - Annual Grant)		10-K		000-51222	February 13, 2020	10.36	X
10.37		Form of RSU Grant Agreement 2015 Plan (Board Members - Incoming Grant)		10-K		000-51222	February 13, 2020	10.37	X
10.38		Distribution Services Agreement dated November 7, 2015 between DexCom, Inc. and AmerisourceBergen Drug Corporation.****		10-K		000-51222	February 13, 2020	10.38	X
10.39		Amendment to the Distribution Services Agreement between Dexcom Inc. and AmerisourceBergen Drug Corporation.****		10-K		000-51222	February 13, 2020	10.39	X
10.40		Third Amendment to Office Lease between DexCom, Inc. and John Hancock Life Insurance Company, dated January 9, 2019.****		10-K		000-51222	February 13, 2020	10.40	X
10.41		Fourth Amendment to Office Lease between DexCom, Inc. and Sequence Tech. Center CA LLC, dated September 9, 2019.****		10-K		000-51222	February 13, 2020	10.41	X
10.42		Fifth Amendment to Office Lease between DexCom, Inc. and Sequence Tech. Center CA LLC, dated October 21, 2019.		10-K		000-51222	February 13, 2020	10.42	X
21.01		List of Subsidiaries							X
23.01		Consent of Independent Registered Public Accounting Firm							X
24.01		Power of Attorney (see signature page of this Form 10-K)							X



Exhibit Number		Exhibit Description		Incorporated by Reference		Provided Herewith
Form	File No.		Date of First Filing		Exhibit Number
31.01		Certification of Chief Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a).				X
31.02		Certification of Chief Financial Officer Pursuant to Securities Exchange Act Rule 13a-14(a).				X
32.01		Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350 and Securities Exchange Act Rule 13a-14(b).***				X
32.02		Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 and Securities Exchange Act Rule 13a-14(b).***				X
101.INS		XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document				X
101.SCH		XBRL Taxonomy Extension Schema Document				X
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document				X
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document				X
101.LAB		XBRL Taxonomy Extension Label Linkbase Document				X
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document				X



*	Represents a management contract or compensatory plan.
**	Confidential treatment has been requested for certain portions of this document pursuant to an application for confidential treatment sent to the Securities and Exchange Commission. Such portions are omitted from this filing and were filed separately with the Securities and Exchange Commission.
***	This certification is not deemed “filed” for purposes of Section 18 of the Securities Exchange Act, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except to the extent that DexCom specifically incorporates it by reference.
****	Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.

Previous: Item 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES · Next: Item 16. FORM 10-K SUMMARY